Sidley Austin > Hong Kong, Hong Kong > Firm Profile
Sidley Austin Offices

LEVEL 39, TWO INTERNATIONAL FINANCE CENTRE
8 FINANCE STREET, CENTRAL
HONG KONG
Hong Kong
- Go to...
- Rankings
- Firm Profile
- Lawyer Profiles
- Focus On
Sidley Austin > The Legal 500 Rankings
Hong Kong > Capital markets (debt) Tier 2
A ‘market leader in the PRC property sector’, Sidley Austin‘s involvement for real estate companies on the Mainland on their primary issuances has now led to the team being very active on formal restructuring and liability management efforts, following well-publicized economic head winds impacting the sector. Combining ‘superb knowledge and experience in the context of market practice, with strong technical skills’, Renee Xiong and Carrie Li are pivotal to this work, at times forming a part of a multi-disciplinary, multi-office team with lawyers on the Mainland and London. The team has also handled some notable new issuances outside of the property sector, with Li recently advising The Export-Import Bank of China on its $1.5bn bond issuance, the first time in several years it has returned to the overseas debt capital market to issue bonds publicly. Splitting his time between Singapore and Hong Kong, Matthew Sheridan leads the overarching Asia capital markets offering.Practice head(s):
Matthew Sheridan
Other key lawyers:
Testimonials
‘The firm has been the market leader in the PRC property sector in its practice. They have very in-depth understanding of latest development of the sector, and have been able to provide creative solutions to the company.’
‘The team members are technically sound and possess up-to-date knowledge of market practices.’
‘Renee Xiong and Carrie Li are very hands-on in representing their clients and you can tell that clients trust them a lot. They combine superb knowledge and experience in the context of market practice, with strong technical skills.’
‘Renee Xiong is very technically sound, committed and is able to deliver a high-quality service.’
Key clients
Central China Real Estate Limited
China Cinda (2020) I Management Limited
China CITIC Bank International Limited
Ganglong China Property Group Limited
Guangdong – Hong Kong Greater Bay Area Holdings Limited
Guangzhou R&F Properties Co., Ltd.
JY Grandmark Holdings Limited
Modern Land (China) Co., Limited
Nine Dragons Paper (Holdings) Limited
Powerlong Real Estate Holdings Limited
RiseSun Real Estate Development Co., Ltd.
Sunac China Holdings Limited
The Export-Import Bank of China
Zensun Group Limited
Zhongliang Holdings Group Company Limited
Work highlights
- Represented Sunac China Holdings Limited in connection with its offering of $1bn convertible bonds due 2032 and $2.75bn zero-coupon mandatory convertible bonds due 2028, as well as multiple series of notes with high-yield covenants through its offshore debt restructuring. These issuances are part of Sunac’s complex restructuring transaction implemented through a scheme of arrangement in Hong Kong.
- Represented Guangzhou R&F Properties Co. in connection with the consent solicitation with respect to the proposed amendments to its three series of US dollar-denominated notes (the Senior Notes) with an aggregated outstanding principal amount of approximately $5.7bn issued by its offshore subsidiary Easy Tactic Limited.
- Represented The Export-Import Bank of China in its offering of $1.5bn 3.875% notes due 2026 under the Export-Import Bank of China US$27 billion Medium-Term Note program. This is the first time in four years that the Export-Import Bank of China has returned to the overseas debt capital market to issue bonds publicly.
Hong Kong > Capital markets (equity) Tier 2
Positioning itself very much at the forefront of the new economy space, the ‘technically strong’ team at Sidley Austin delivers ‘high-quality work’ for an issuer-focused client base seeking to list on the HKEX. The team has been at the vanguard of the new listing rules affecting both pre-revenue healthcare and specialist tech companies, having had a key role in actually shaping the 18C listing rules through its interactions with the regulator. The ‘very commercial’ Claudia Yu, who is ‘particularly capable at advising on novel rules and pioneer transactions’, has been key to much of this work, including her lead role for QuantumPharm Inc., in what is the first specialist technology company expected to list under the new Chapter 18C. Himself a former scientist, Meng Ding has deep industry understanding and is also key to much of this work, excelling in drafting the underlying prospectuses. The ‘technical, commercial and responsive’ Sherlyn Lau is also key to the firm’s growing success and co-heads team alongside Constance Choy.Practice head(s):
Constance Choy; Sherlyn Lau
Other key lawyers:
Testimonials
‘The team consistently delivers high-quality work.’
‘This technically strong team stands out as having the experience and ability in handling complex structures and is able to offer solutions for novel and common issues alike.’
‘Sherlyn Lau is technical, commercial and responsive. Great problem solver.’
‘The very commercial Claudia Yu acts as a good conduit between the issuers and the regulators. She is particularly capable of advising on novel rules and pioneer transactions.’
‘Claudia Yu is very knowledgeable about HK listing rules and other regulations She has strong access to both HKEX and the SFC vetting team she always stands by to help address challenging questions.’
Key clients
BaTeLab Co., Ltd.
Qyuns Therapeutics Co., Ltd.
QuantumPharm Inc.
CITIC Securities (Hong Kong) Limited
Mobile-health Networks Solutions
ICBC International Capital Limited
LC Logistics, Inc.
China International Capital Corporation Hong Kong Securities Limited
China Securities (International) Corporate Finance Company Limited
Ryde Group Ltd
Haitong International Capital Limited
Huatai Financial Holdings (Hong Kong) Limited
Bitdeer Technologies Holding Company
MicroPort Cardiac Rhythm Management Limited
Noco-Noco Pte. Ltd.
China Merchants Securities (HK) Co., Limited
Shenzhen IVF Hospital Management Group Co., Ltd.
Gala Technology Holding Limited
US Tiger Securities, Inc.
Work highlights
- Advising QuantumPharm Inc. in connection with the proposed IPO on the Main Board of the HKEX.
- Advised BaTeLab Co. in its IPO and H share listing on the Main Board of the HKEX.
- Advised Qyuns Therapeutics Co. on its IPO and H shares listing on the Main Board of the HKEX under Chapter 18A of the Listing Rules.
Hong Kong > Investment funds Tier 2
The ‘very responsive and technically competent’ team at Sidley Austin has proactively kept abreast of fluctuating market conditions, successfully adapting and modifying its approach to best-suit its GP-focused client base. While fund raisings for private equity buyout funds have suffered somewhat of a hit due to economic headwinds, the firm has been front and centre in offering tangible solutions to GPs, whether it be in the form of establishing continuation funds, spin-off deals, as well as helping to restructure existing portfolios. The team has also, for example, been involved in an increasing number of credit fund mandates, a reflection of higher interest and tightening bank regulation. The ‘outstanding’ David Lee has been integral to many of the strategic solutions for GP clients where he is effectively able to combine fund structuring and M&A expertise, for example, in the context of a manager spin-off.Other key lawyers:
David Lee; Dominic James; Huberta Chow; Misha Yang
Testimonials
‘It is a very responsive and technically competent team.’
‘David Lee is very commercial and committed to the process and deal.’
‘David Lee is an outstanding funds lawyer who is able to build rapport with clients and always willing to go the extra mile. He is able to give good legal advice while still being mindful of commercial considerations.’
Key clients
UBS AG
BlackRock
Morgan Stanley
Ward Ferry
Canyon Partners
Sequoia Capital
Heyokha Brothers
Infini Capital Management Limited
DH International Limited
DASH Management Limited
NonaVerse (Hong Kong) Limited
Proterra Investment Advisors (Singapore) Pte Ltd
Hong Kong > Restructuring and insolvency Tier 2
Showcasing extensive expertise on both the debtor and creditor sides, Sidley Austin is described as ‘experienced and effective’ when handling cross-border restructurings, primarily concerning companies’ offshore debt. Additionally, the practice is well equipped to manage winding up petitions and Hong Kong schemes of arrangement. Leveraging her ‘extensive knowledge’, Renee Xiong is a key contact for negotiating structuring terms for debt securities, Carrie Li is a capital markets expert, while Desmond Ang stands out for his work on insolvencies and distressed scenarios. Olivia Ngan and Joshua Oeij are both highlighted as key ports of call.Other key lawyers:
Matthew Sheridan; Renee Xiong; Carrie Li; Desmond Ang; Olivia Ngan; Joshua T. Oeij; Ibrahim Babiker
Testimonials
‘Experienced and effective team with an outstanding client list’
‘Desmond Ang stands out for contentious insolvency and has been the leading practitioner in this area during the China property downturn.’
‘The restructuring team is professional and always provides prompt response and support to the client including finance restructuring, litigation and compliance.’
‘Renee Xiong – possesses good, updated knowledge and can protect the interests of the client.’
‘Olivia Ngan – possesses good, updated knowledge, works well with the client, and attends to all details.’
‘Sidley Austin LLP acts as the Company’s counsel on Hong Kong Law and New York Law in connection with the parallel Scheme of the Company in Bermuda and Hong Kong. Sidley team provides quality services, able to deliver works on time and assist the Company to resolve many issues and provide valuable advice where necessary.’
‘Renee Xiong, Partner of Sidley Austin LLP, possesses extensive knowledge and is technically sound. She shows initiative, is committed, and is able to lead the team members to provide quality services. Renee provides value-added services and maintains good relationship with clients.’
Key clients
Sunac China Holdings
China Evergrande Group
Modern Land (China) Co. Limited
China Fortune Land Development (CFLD)
Kaisa Group
Ting Chuan (Cayman Islands) Holding Corporation
Fantasia Holdings Group
Logan Property Group
Zhenro Properties Group Limited
Dafa Properties Group Limited
Shunsun Holdings Group
Va Land Investment Group Corporation
Zhongliang Holdings Group Company Limited
Work highlights
- Advised Sunac in successfully completing the restructuring of its US$10.2 billion in offshore debt.
- Advising Kaisa on its potential restructuring of approximately US$16.1 billion in offshore debt.
- Advising Fantasia on its potential restructuring of approximately US$4 billion in offshore debt.
Hong Kong > Banking and finance Tier 3
Noted for its expertise across the life sciences, real estate, energy and retail sectors, Sidley Austin provides representation to borrowers and handles hybrid fund financing and debt financing mandates, with additional experience in sustainable bonds. Practice leader Olivia Ngan acts for Chinese borrowers and lenders, boasting demonstrable expertise in credit finance transactions in China. Ngan is ably supported by Alan Wong, who focuses on direct lending by funds, structured lending, acquisition finance, and real estate finance.Practice head(s):
Olivia Ngan
Other key lawyers:
Key clients
R-Bridge Healthcare Fund
CBC Group
Shimao Group Holdings Limited
China Oil And Gas Group Limited
Golden Eagle Retail Group Limited
Country Garden Holdings Company Limited
Agile Group Holdings Limited
Work highlights
- Advised R-Bridge Healthcare Fund (RBF) on a US$120 million “hybrid” fund financing granted by Natixis Corporate & Investment Banking through its Hong Kong branch and Mashreqbank PSC.
- Represented Shimao Group Holdings Limited (Shimao Group) and its subsidiary Brand Rise Limited, as borrower, in the successful restructuring of its original $4.5 billion HKD project loan facilities in respect of the Four Points by Sheraton Hong Kong, Tung Chung Hotel.
- Represented China Oil and Gas Group Limited in the successful closing of its $300 million sustainability-linked term loan facility, funded by eight international banks and arranged by China CITIC Bank International Limited and Ping An Bank Co., Ltd., as joint mandated lead arrangers, bookrunners, and underwriters.
Hong Kong > Fintech and financial services regulatory Tier 3
Sidley Austin’s multi-disciplinary investment funds team provides ‘comprehensive, clear and pragmatic advice’ to many of the largest fund managers establishing funds throughout Asia. In this context, clients benefit from the knowledge that not only will they be well-served on sophisticated fund structures but also receive the regulatory overlay on these mandates. The ‘approachable and responsive’ Dominic James provides risk management/compliance advice and is also well-versed at handling attendant regulatory enforcement actions. Outside of the asset management arena, Stephanie Chan provides ‘practical and strategic advice’ to Hong Kong-listed companies facing down regulatory investigations, regularly working alongside ‘very committed and dedicated’ senior associate Adrian Tang.Other key lawyers:
Testimonials
‘The team has a deep understanding of the latest trends and developments in the regulatory space. In particular, the team has demonstrated a high level of awareness of the latest regulatory developments and enforcement actions relevant to our regulatory matters.’
‘They have provide comprehensive, clear and pragmatic advice.’
‘The very approachable and responsive Dominic James looks at issues at different angles making sure every essential aspects are covered for the benefit and effective risk management of clients.’
‘Stephanie Chan is a problem solver. She provides us with solutions that best suit our needs, whilst being mindful of our costs concern and ensure that our case is being conducted in the most cost-effective and efficient way.’
‘Stephanie Chan is a thought leader in both the regulatory and litigation fields. She has a proven track record in securing favourable outcomes and resolving complex litigation and regulatory matters for our company.’
‘Stephanie Chan’s deep knowledge, practical and strategic advice and responsiveness make all the difference.’
‘Adrian Tang is very committed and dedicated, and handles matters efficiently and cost-effectively.’
Key clients
JQ Investments (HK) Ltd
International Bank for Reconstruction and Development (World Bank)
Arthur J. Gallagher & Co.
SwissRe Group
Work highlights
Hong Kong > Dispute resolution: international arbitration Tier 4
Sidley Austin often acts for a lucrative client base of blue-chip clients, Chinese corporates and state-owned enterprises on major bet-the-company multi-jurisdictional mandates. Yan Zhang regularly represents multinational clients across a wide variety of industries, including healthcare, TMT and financial services, while Desmond Ang has a growing restructuring and insolvency practice, representing both debtors and creditors.Practice head(s):
Desmond Ang; Yan Zhang
Testimonials
‘The Sidley team has always been a well-known and leading team in the market. It is also highly sensitive to the latest industry developments and can provide high-quality services in the first place for emerging industries.’
‘Desmond Ang has a high sensitivity to both law and business, and is good at using legal analysis to resolve business disputes or facilitate business transactions. In normal cooperation, he always responds to clients’ questions in the first place, winning high praise from clients.’
‘The team has strength in depth with three talented and active partners.’
‘Yan Zhang combines a charming manner with deep arbitration expertise.’
‘Desmond Ang is serious and knowledgeable.’
‘Zhang Yan has extensive experience in dispute resolution and his service attitude and quality are excellent.’
‘Very responsive, smart, solution-oriented, good language skills.’
Key clients
I-Mab Biopharma Co., Ltd.
Ting Chuan (Cayman Islands) Holding Corp
China Evergrande Group
Work highlights
- Successfully defeated damages claims for a global biotech company, I-Mab Biopharma, in a US$340 million New York-seated ICC arbitration against its U.S. clinical research partner.
- Represented Ting Chuan (Cayman Islands) Holding Corp (Applicant) in a privy council decision. The Judicial Committee of the Privy Council handed down its judgment in the case of Ting Chuan (Cayman Islands) Holding Corp v FamilyMart China Holding Co Ltd on September 20, 2023.
Hong Kong > Corporate (including M&A) Tier 5
Regularly collaborating with the firm’s US and China groups, Sidley Austin continues to be active within the tech and automotive industries. Practice co-head Constance Choy is recommended for her broad expertise spanning the life sciences and financial services sectors, while co-head Raymond Oh is well-placed to assist with public and private M&A and fund formation mandates, in addition to de-SPAC transactions. Noted for providing ‘clear, persuasive and practical‘ advice, Christopher Cheng also stands out due to his vast knowledge of public takeovers and share buy-back mandates.Practice head(s):
Constance Choy; Raymond Oh
Other key lawyers:
Testimonials
‘Sidley Austin’s corporate team assists us in handling a wide range of transactions, from private equity-related investments to complex cross-border deals. They have a deep understanding of customer needs and provide a high standard of service.’
‘The team is able to anticipate potential issues and proactively develop creative solutions to address them. Their responsiveness, attention to detail, and commercial acumen have been invaluable in navigating the complex legal and regulatory landscape. Raymond Oh has extensive experience in M&A and corporate finance transactions. He is quite hands-on and always puts the clients’ interest first.’
‘Sidley Austin’s team is very experienced and has handled complex corporate legal matters. They are familiar with listing rules and other listing cases, and have provided a lot of practical suggestions for the company’s legal matters. At the same time, we highly appreciate the excellent diversity of personnel and in-depth understanding of various industries.’
‘Christopher Cheng has extensive experience in corporate legal affairs. His advice is clear, persuasive and practical, and played a decisive role in the company’s resumption of trading.’
Key clients
BGX Group Holding Limited
Noco-Noco Pte. Ltd.
SanReno Therapeutics Holdings Limited
Resolian
China Renaissance Securities (Hong Kong) Limited
Zylox-Tonbridge Medical Technology Co., Ltd.
TMF Hong Kong Limited
symplr software LLC
Geely Automobile Holdings Limited
Geely Group Limited
Hony Capital
GDS Holdings Ltd.
Golden Eagle Retail Group Limited
Guangzhou R&F Properties Co., Ltd.
Work highlights
- Represented BGX Group Holding Limited in connection with the proposed subscription of 187.6 million new shares from BC Technology Group Limited under the specific mandate.
- Representing noco-noco Pte. Ltd. on its business combination with Prime Number Acquisition I Corp.
- Represented SanReno Therapeutics Holdings Limited on its acquisition by Novartis.
Hong Kong > Private equity Tier 5
Regularly collaborating with the firm’s US, China, and Singapore teams, Sidley Austin is recommended for its strong focus on private equity driven transactions within the life sciences and tech sectors. The group’s workload primarily consists of series financing, investment, and acquisition mandates. Practice head Raymond Oh maintains a broad practice spanning pre-IPO investments and PIPE transactions.Practice head(s):
Raymond Oh
Testimonials
‘The continuity of the relationship is important so the the team understand our business needs. Raymond Oh and his team is quick to get on call and provide solutions in various agreements.’
‘Raymond Oh and his team are always able to offer multiple views of different stakeholders.’
‘They have a seamless team working across Singapore and Hong Kong on PE engagements. They did a good job in managing the complex DD and the documentation was also very complex.’
Key clients
OnCusp Therapeutics, Inc.
Medicxi
Cellomics
symplr software LLC
Stonepeak Infrastructure Partners
Blue InCube
Work highlights
- Represented OnCusp Therapeutics, Inc. in the oversubscribed US$100 million (more than RMB700 million) Series A financing round.
- Represented Cellomics in its Series B+ financing.
- Represented Medicxi in its US$40 million investment in D3 Bio, a biotechnology company based in China.
India > Foreign firms Tier 3
China > Life sciences and healthcare: foreign firms
Sidley Austin LLP's lawyers ‘give clients very practical advice’. The practice has a significant market reputation for life sciences regulatory work; and it is home to specialists in licensing-related deals, series financings, M&A, IPOs, and fundraising. The practice additionally assists multinational pharmaceutical and healthcare companies with both government and internal investigations. Chen Yang in Beijing routinely acts for international pharmaceutical, medical device, agricultural, food, and cosmetics companies. Working across the Beijing and Hong Kong offices, Lei Li advises on product registration, clinical trials, distribution, licensing, co-marketing, M&A and spin-offs; and Ruchun Ji acts for emerging and innovative life sciences sector companies throughout their life cycles. Based in Hong Kong and Singapore, Yuet Ming Tham is the firm’s Asia-Pacific compliance and investigations practice head.Practice head(s):
Lei Li; Chen Yang
Other key lawyers:
Testimonials
‘Sidley’s life sciences team has been deeply involved in the industry for many years and has accumulated rich practical experience in various fields, such as M&A, regulatory, compliance, and antitrust.’
‘Sidley’s lawyers give clients very practical advice based on the actual situation of Chinese business, which is very rare.’
‘Chen Yang has extensive experience in the regulatory field.’
‘Lei Li has outstanding experience.’
Key clients
Connect Biopharma
Impact Therapeutics
OnCusp Therapeutics
Resolian
RDPAC
Sanofi Aventis China
SanReno Therapeutics Holdings
Takeda China Investment Co
Zylox-Tonbridge Medical Technology
Work highlights
- Advised Sanofi Aventis China on a successful collaboration with Shanghai Pharma, through which Shanghai Pharma will import, distribute and promote 21 Sanofi drugs.
- Advised RDPAC on the development of three highly influential industry compliance guidelines, including a digital health industry guideline.
- Advised SanReno Therapeutics Holdings on its acquisition by Novartis.
Singapore > Capital markets: equity and debt: foreign firms
Sidley Austin LLP is a major player in Asia capital markets with two senior figures in Singapore; Asia capital markets head Matthew Sheridan and Manoj Bhargava. Sheridan has been at the forefront of high-yield debt in Asia Pacific over the last two decades and remains a force in the Greater China high-yield market. Bhargava is a leader in India equity and debt offerings, advising on 10 offerings for Indian companies in 2023. Elected to the partnership in 2022, Alexius Chong has built a fine reputation in Southeast Asia debt and equity transactions. With the depth of talent in the Singapore office, the firm has established itself across multiple debt and equity product areas, including IPOs, convertible bonds, investment grade debt, high-yield bonds, liability management, distressed debt restructurings and going private transactions. Key markets include Singapore, India, Indonesia, Japan, Malaysia, the Philippines and Vietnam. In headline deals, the office advised on the largest IPO in Indonesia in 2023 (PT Amman Mineral Internasional) and the largest India IPO in 2023 (Mankind Pharma).Practice head(s):
Matthew Sheridan; Manoj Bhargava
Other key lawyers:
Key clients
No Va Land Investment Group Corporation
J.P. Morgan
PT Mandiri Securities
PT. BNI Sekuritas
CLSA
DBS Bank
ING
Jefferies
ContextLogic
BofA Securities
Brookfield India Real Estate Trust
PT Indika Energy
Kotak Mahindra
ICICI Securities
Work highlights
- Advised the joint lead managing underwriters on the initial public offering (IPO) and listing of shares on the Indonesia Stock Exchange (IDX) of PT Amman Mineral Internasional (AMI).
- Representing No Va Land Investment Group Corporation, one of the largest listed real estate developers in Vietnam, in the restructuring of its Singapore Exchange-listed (SGX) $300m.
- Represented the underwriters in the $2.15bn follow-on public offering of equity shares of Vodafone Idea, India’s largest ever follow-on public offering of equity shares.
Singapore > Investment funds: foreign firms
The team at Sidley Austin LLP in Singapore is well-placed to collaborate with the firm's offices in Hong Kong, Beijing, Shanghai, Tokyo and Sydney on fund formation mandates, showcasing notable expertise in private equity funds and hedge funds. Based in Hong Kong, Effie Vasilopoulos leads the APAC investment funds group. Key contacts on the ground include Josephine Law, who focuses on registered fund transactions and regulatory matters, and Patrick Liu, whose relocation to Singapore strengthens the team's private equity fund formation offering.Practice head(s):
Effie Vasilopoulos
Other key lawyers:
Key clients
EQT
UBS
BlackRock
Loyal Valley Capital
Stonepeak Investment Advisors
Proterra Investment Partners
Dymon Asia Capital
AllianceBernstein
Verition Fund Management
Pacific Eagle Group
PAG
PIMCO
Oxbow Capital Management
King Street Capital Management
Point72
Investcorp
Citadel
Asia Pacific: Regional International Arbitration > Leading firms
Sidley Austin covers international arbitration from its offices in Singapore and Hong Kong, where it handles a full spectrum of commercial disputes, including ones sitting against a backdrop of US-China relations. Tai-Heng Cheng in Singapore has a track record of claimant-side investor-state arbitration work. Greater China related disputes are key areas of activity for Desmond Ang, Friven Yeoh and Yan Zhang, all of whom are based in Hong Kong.Work highlights
Sidley Austin > Firm Profile
Chair of Executive Committee: Michael J. Schmidtberger
Chair of the Management Committee: Yvette Ostolaza
Number of lawyers worldwide: Over 2,300
Number of partners: Over 650
Asia Pacific Offices: Beijing, Hong Kong, Singapore, Sydney, Tokyo
International Offices: Boston, Brussels, Century City, Chicago, Dallas, Geneva, Houston, London, Los Angeles, Miami, Munich, New York, Palo Alto, San Diego, San Francisco, and Washington, DC
Firm Overview:
Sidley is one of the few international law firms to have continuously maintained on-the-ground capabilities to serve clients in Asia Pacific for 40 years. The firm now has approximately 230 legal professionals based in six offices across the region, and provides Singapore, US, Hong Kong, English and Japanese law advice to clients where and when they need it.
Main Areas of Practice:
-
-
- Antitrust/Competition
-
-
-
- Capital Markets
-
-
-
- Energy and Infrastructure
-
-
-
- Finance
-
-
-
- Investment Funds
-
-
-
- Life Sciences
-
-
-
- Litigation, Arbitration, Trade & Advocacy
-
-
-
- Mergers & Acquisitions
-
-
-
- Private Equity & Venture Capital
-
-
-
- Regulatory & Compliance
-
-
-
- Restructuring & Insolvency
-
Lawyer Profiles
Photo | Name | Position | Profile |
---|---|---|---|
![]() |
Stephanie Chan | Partner | View Profile |
![]() |
Meng Ding | Partner | View Profile |
![]() |
Renee Xiong | Partner | View Profile |
![]() |
Claudia Yu | Partner | View Profile |
Focus On
Navigating Regulatory Risks for Hong Kong Listed Issuers and Directors: Latest Trends, Developments, and Insights
1. An overview of the Securities Regulators in Hong Kong
As a major international finance center, Hong Kong has a sophisticated regulatory regime. Hong Kong listed companies are primarily supervised and monitored by the Securities and Futures Commission (SFC) and the Hong Kong Exchanges and Clearing Limited (HKEX). The SFC and HKEX are increasingly deepening their collaboration and working with other law enforcement agencies, such as the Accounting and Financial Reporting Council (AFRC), the Hong Kong Police Force, and the Independent Commission Against Corruption (ICAC), to investigate potential misconduct and take disciplinary and enforcement actions.
As to the general purview of the main regulators for Hong Kong listed companies:
(a) The SFC has a wide statutory power of investigation and enforcement to examine cases of corporate misconduct. While it also plays a separate role in licensing and regulating financial activities and in supervising the conduct of financial institutions and licensed corporations, its Enforcement Division undertakes substantive investigations into breaches of Hong Kong’s Securities and Futures Ordinance (SFO), including market misconduct and other statutory offenses.
(b) The HKEX is the key body for regulating listed companies in Hong Kong. The HKEX’s roles include establishing, promulgating, and administering the Hong Kong Listing Rules. From a regulatory perspective, this often involves investigation of noncompliance with the Listing Rules requirements and breaches of directors’ duties and taking disciplinary actions, if required.
In addition to the SFC and HKEX, the AFRC, while primarily regulating the conduct of accounting professionals, including certified public accountants and auditors, also has a statutory mandate to make inquiries into Hong Kong listed companies whose financial reporting are potentially noncompliant with regulatory requirements.
These regulators also collaborate with their overseas counterparts to extend regulatory cooperation with the overall aim to better maintain the integrity of the Hong Kong securities market.
2. SFC and HKEX — General Nature of Regulatory Investigations
Where there is potential noncompliance by a Hong Kong listed company under the Listing Rules and the SFO, it is common for the SFC and the HKEX to collectively take an interest in the listed company’s business affairs and conduct parallel investigations. As noted above, the regulators’ respective mandate and investigative powers are different, so it is worthwhile for listed issuers and their directors to have an appreciation for the different approaches that the regulators may adopt in conducting their investigations.
(a) SFC
The SFC’s investigative powers are based on the SFO, and the SFC can compel subjects of an investigation or any persons believed to possess relevant evidence to produce records and documents, provide written explanations, attend in-person interviews, and to render all reasonable assistance to facilitate the SFC’s investigations. The SFC is also able to apply for a search warrant from the court to conduct unannounced dawn raids to search and seize records and documents from specified premises. Where the SFC is investigating a listed company, it is commonly looking to identify potential misconduct related to audit issues, improper commercial transactions, market misconduct behavior, breaches of disclosure requirements, and other activities contrary to the interests of the investing public. Failure of issuers and directors to cooperate with the SFC’s investigation may constitute a criminal offense.
Upon establishing that there has been a breach of statute or regulatory requirements, depending on the nature of the offense, the SFC may initiate civil proceedings before the Market Misconduct Tribunal or commence criminal or civil proceedings in court against the parties responsible for the misconduct and to seek appropriate remedies and sanctions against the wrongdoers, including but not limited to disqualification orders, compensation orders, fines and criminal sentences.
(b) HKEX
The HKEX’s investigative powers are derived from the Listing Rules. The HKEX has the authority to review, on an ongoing basis, whether listed issuers continue to meet the necessary requirements for them to remain suitable for listing and, if not, to take steps to cancel their listing. The focus of the HKEX’s inquiries generally revolves around potential breaches of the Listing Rules, and queries may be directed to the issuers and their directors to provide written submissions and supporting documents.
Upon establishing that there has been a breach of the Listing Rules, the HKEX may bring disciplinary actions and impose appropriate sanctions on listed issuers, their directors, and senior management, such as a private reprimand, public criticism, public censure, director unsuitability statement, or prejudice to investors’ interests statement. The HKEX may also refer the matter to the SFC, other regulatory authorities or professional bodies for further action.
3. Recent enforcement cases and trends
(a) Ramp-and-Dump Scams
Ramp-and-dump scams involve strategic manipulation of the share price and trading volume of vulnerable listed issuers. Typically, sophisticated cross-border syndicates would artificially ramp up the price of the targeted issuer through spreading favorable news on social media to induce investors to purchase the shares, after which the syndicates would dump all of their shares at an artificially high exit price, causing the share price to collapse and leaving other investors with significant losses. Recently, the SFC, the ICAC, and the Hong Kong Police Force have been working together to target ramp-and-dump syndicates and conducting joint operations to arrest suspected syndicate members, including senior managers of listed companies, accounting professionals, and brokers.
In July 2024, in the case of HKSAR v Sit Yi Ki and others [2024] HKCFI 1937, the Hong Kong courts imposed the heaviest jail sentence, ranging from 52 to 80 months of imprisonment, on market manipulation since the SFO came into effect in 2003 after three perpetrators of a complex cross-border ramp-and-dump syndicate were found guilty of conspiracy to carry out false trading in the shares of shares of Ching Lee Holdings Limited. A more detailed discussion of this landmark case can be accessed at Sidley Austin’s website.
(b) IPO Misconduct
Another enforcement focus relates to newly listed issuers’ usage of initial public offering (IPO) proceeds in a manner inconsistent with originally disclosed business plans, without making further proper disclosure. Regulators have identified the following alarming scenarios:
- unusually high expenses not disclosed in listing documents and potentially disguised as IPO consultancy service fees, underwriting commissions, and other listing expenses (see the SFC and HKEX’s Joint Statement on IPO-related Misconduct dated May 20, 2021); and
- questionable investments or loans using a significant portion of the IPO proceeds without commercial rationale and on unfavorable terms to the issuer (see the HKEX’s Review of Issuers’ Annual Reports 2023 issued in January 2024).
In March 2024, the HKEX took disciplinary action and imposed director unsuitability statements against the former executive directors of Global Uin Intelligence Holdings Limited (stock code 8496) for misappropriation of IPO proceeds for their own use through a sham arrangement that was not disclosed in the issuer’s listing documents (see the HKEX’s Statement of Disciplinary Action dated March 5, 2024). A more detailed discussion of this joint enforcement case can be accessed at Sidley Austin’s website.
(c) Dubious Financial Arrangements
Misconduct regarding loans, advances, prepayments, and other similar arrangements made by listed issuers remains under close scrutiny by regulators. On July 13, 2023, the SFC and the AFRC issued a Joint Statement addressing this issue. On April 25, 2024, the HKEX issued its Statement of Disciplinary Action against China Ecotourism Group Limited (stock code 1371) and its current and former directors concerning misconduct in making questionable loans and investments that constituted undisclosed connected transactions, caused significant impairment loss to the issuer, and revealed its inadequate internal controls. On April 30, 2024, the HKEX dedicated the April 2024 edition of its Enforcement Bulletin to the topic, highlighting common red flags at the pre-loan, post-loan, and recovery stages of the lending process. The regulators consider that lending practices of listed issuers should be comparative to the approach adopted by the banking industry to protect investors’ interests. A more detailed discussion of these developments by the Sidley Austin team can be found here and here.
(d) INEDs
In November 2023, the HKEX published “A Snapshot of INEDs’ Roles and Responsibilities” to remind independent nonexecutive directors (INEDs) of their duties under the Listing Rules and the Corporate Governance Code as an extra pair of eyes, including to oversee the listed issuer’s business decisions, risk management, and internal controls as well as to take proactive steps to ensure the truthfulness and accuracy of the issuer’s financial statements.
In the same month, the SFC obtained a three-year disqualification order against a former INED of China Candy Holdings Limited (stock code 8182) in Securities and Futures Commission v. Xu Jinpei and Others [2023] HKCFI 2908 for his failure to discover overstatements in the issuer’s interim and annual reports and to supervise the bank balances provided during the audit process. The former INED was found to be in breach of his fiduciary duties to the issuer and had caused prejudice to investors’ interests.
It is expected that INEDs’ compliance with their directors’ duties will continue to be closely scrutinized alongside executive directors of listed issuers. A more detailed discussion can be found at Sidley Austin’s website.
4. Common misconceptions and pitfalls for issuers and directors
Directors of Hong Kong listed issuers should generally be aware of the statutory and regulatory obligations as well as their directors’ duties. However, in practice, there can be pitfalls such as the following misconceptions that may become apparent only when noncompliance with the regulatory requirements is discovered.
(a) Auditors already considered internal control issues as part of the annual audit, so separate internal control reviews are unnecessary.
It is worth noting that the primary mandate of external auditors in an annual audit context is to scrutinize and verify the issuer’s financial accounts. Instead of placing excessive reliance on the lack of adverse findings on internal control issues in an annual audit context, Hong Kong listed issuers should regularly review the internal control system in place with a particular focus on compliance with the regulatory requirements in Hong Kong under the Listing Rules and SFO to ensure it remains effective and continues to serve its purpose, and such a review should be conducted at least annually. Continuous monitoring and assessment of the internal control system is essential for maintaining good corporate governance.
(b) It is sufficient for there to be a focus on corporate governance concerning the operational side of the business.
Even where Hong Kong listed issuers maintain good corporate governance at the business operational level, it is not uncommon for the issuer’s group to lack established and maintained policies and procedures to ensure compliance with the Hong Kong Listing Rules. They may also lack internal controls for detecting red flags and other potential misconduct. It is also important to ensure that internal policies and systems are effectively implemented.
(c) No disciplinary action will be taken when there is no loss.
A common misconception in a disciplinary context is that regulators would not take enforcement action against the issuer or its directors if investors suffered no loss. While investor loss is one of the key factors regulators consider when assessing the severity of the misconduct and the necessity to take disciplinary action, it is more of an aggravating factor than a mitigating factor. The absence of loss would generally be insufficient to exculpate the issuer or its directors of an identified breach or misconduct and avoid potential disciplinary actions and sanctions.
(d) INEDs should not bear responsibility for matters as they are not involved in the daily operation of the company.
A frequently raised defense by INEDs in response to allegations of a failure to discharge their directors’ duties is that they were not involved in the daily operation of the company. It is the expectation of the regulators that INEDs must be proactive in raising inquiries regarding the business operations of the company and identifying potential red flags. Additionally, they are expected to regularly review the adequacy of the issuer’s internal controls and corporate governance framework to ensure they are sufficient for achieving regulatory compliance.
(e) Regulatory investigations are just routine procedures, and it is unnecessary to devote time and resources to resolving them.
In general, a regulatory investigation may be triggered for a range of underlying reasons, and it may also be pursuant to a regulatory complaint, disclosures in the issuer’s announcements, or a whistleblower’s report. The securities regulators generally commence their inquiries pursuant to a suspicion of potential misconduct or noncompliance. It is paramount that the issuer and its board take inquiries and investigations seriously and cooperate with the regulators. Some common pitfalls for directors in a regulatory investigation context include underestimating the scale, scope, and impact of the investigation; failing to allocate sufficient workforce and resources to resolve the inquiries; and failing to engage and consult professional parties to manage and advise on the process at an early stage.
5. Practical tips and insights
(a) Cooperation with regulators
(i) Providing true and complete information and documents. This includes taking early and proactive steps to preserve evidence and providing full disclosure of the relevant information.
(ii) Taking a proactive approach by devoting sufficient resources to investigating the matter and responding to the regulatory inquiries. This may involve engaging professional parties, such as legal advisers, forensic investigators, and internal control reviewers as necessary to assist with factfinding and responding to the regulators’ inquiries.
(iii) Taking appropriate remedial measures. If the issuer identifies any specific issues constituting internal control failures, it should consider implementing remedial measures to enhance its internal controls and procedures. The issuer should conduct an independent internal control review to identify possible internal control failures and the necessary remedial measures.
(iv) Initiating settlement. If the parties intend to settle, they should approach the regulators as early as practicable. Some of the typical factors that ought to be considered include the strength of the regulator’s cases, the time and costs to be incurred in a prolonged regulatory investigation and potential legal proceedings, possible reputational damage to the company and individuals, and possible penalties to be levied.
(b) Secrecy obligations, document preservation, recordkeeping, and legal professional privilege
(i) Secrecy obligations. Under the SFO, it is a criminal offense for any person to disclose information related to the SFC and HKEX investigations to any other person, save where the disclosure falls under the limited exceptions. Where there is a need for other third parties (e.g. insurers) to know any information in relation to the regulatory investigations, the issuer should seek prior written consent from the regulators for onward disclosure.
(ii) Document preservation. In a regulatory investigation context, it is strongly advisable for the issuer and its directors to take steps to preserve all documents and information potentially relevant to matter being investigated, including electronic records and hard copies. Any intentional destruction of any documents may constitute a criminal offense under Hong Kong law.
(iii) Recordkeeping. Good recordkeeping practices play an important role in ensuring that the issuer is able to adduce contemporaneous evidence in support of its compliance with the regulatory requirements.
(iv) Legal professional privilege. An issuer is not obliged to produce privileged documents to the regulators unless the issuer decides that it is appropriate to waive privilege on a limited basis to facilitate the investigation. Issuers are recommended to seek legal advice to determine whether the relevant materials are covered by legal professional privilege.
(c) Managing SFC interviews
(i) Considerations for attending an interview with the SFC. In an investigation conducted by the SFC, it is common for the SFC to invite directors and senior managers to attend formal interviews. Some of the relevant considerations include the importance of maintaining statutory secrecy obligations in relation to the interview and the individual’s right to claim self-incrimination privilege while still needing to answer all questions posed by the SFC.
(ii) Preparation for an interview with the SFC. Prior to the interview, it is recommended for the interviewee to thoroughly review all the previous written submissions provided to the SFC and consult with legal counsel to ascertain the issues that may be addressed in the course of the interview. As there is no right to remain silence, if a response is potentially self-incriminating, the interviewee should make a claim to assert privilege against self-incrimination as provided for under the SFO before responding to the questions. The interviewee should answer the questions truthfully and concisely, and avoid addressing irrelevant matters that go beyond the scope of the interview.
Authors: Stephanie Chan, Adrian Tang and Celia Chong (Sidley Austin)
- Capital markets (debt)
- Capital markets (equity)
- Investment funds
- Restructuring and insolvency
Firm Rankings
- India > Foreign firms